CTOs on the Move

Glyscend

www.glyscend.com

 
Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.glyscend.com
  • 1812 Ashland Avenue Suite 110
    Baltimore, MD USA 21205
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Glyscend raised $20.5M on 06/11/2020

Similar Companies

BioReliance Corporation

BioReliance Corporation is a contract service organization that provides services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company has two segments, testing and development services and

TEI Biosciences

TEI Biosciences is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.

Clintech Research

Clintech Research is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.